The European Medicines Agency has begun evaluating EU marketing authorization applications (MAAs) for a new batch of investigational drugs, of which two – polyhexanide (Akantior) and aflibercept – are for ophthalmological conditions.
If approved, polyhexanide, from the Italian company SIFI, could become the world’s first approved treatment for the rare, acute...








